The ARL2BP Knockout HT29 Polyclonal Cells are a genetically disrupted polyclonal cell population generated by CRISPR/Cas9-mediated editing of the endogenous ARL2BP locus in HT29 human colorectal adenocarcinoma epithelial cells. This polyclonal pool retains the heterogeneous genetic background of the parental line while introducing targeted ARL2BP gene ablation, providing a physiologically relevant loss-of-function model without clonal isolation artifacts.
The HT29 cell line was established from a primary colorectal adenocarcinoma of a 44-year-old female and displays epithelial morphology characteristic of differentiated intestinal cells. HT29 cells harbor a heterozygous TP53 mutation (p.R273H) and an APC truncating mutation, with wild-type KRAS status, and can undergo enterocytic differentiation upon exposure to butyrate or other stimuli, making them a widely used model for intestinal biology and colorectal cancer research.
ARL2BP encodes an effector of the small GTPase ARL2, localizing to mitochondria where it interacts with the adenine nucleotide translocator ANT1 (SLC25A4) and the voltage-dependent anion channel VDAC1 to regulate the mitochondrial calcium uniporter (MCU) complex. Through ARL2-dependent mechanisms, ARL2BP modulates mitochondrial calcium uptake, maintenance of mitochondrial membrane potential, and ATP production. It also contributes to ciliary function and microtubule organization via tubulin folding cofactors. Upstream regulators include GTP-bound ARL2, cellular ATP levels, and oxidative stress, while downstream targets encompass MICU1, MCU, and mitochondrial fission/fusion machinery. The ARL2BP-ARL2 complex thus integrates cellular energy status with mitochondrial dynamics and calcium homeostasis.
In the HT29 colorectal cancer background, ARL2BP knockout is expected to perturb mitochondrial calcium handling and energy metabolism, potentially affecting the apoptotic threshold and proliferative capacity of these tumor cells. Loss of ARL2BP function may dysregulate the ANT1-VDAC1-MCU axis, leading to altered mitochondrial membrane potential and reactive oxygen species generation. This provides a valuable system to dissect how mitochondrial dysfunction influences colorectal cancer cell survival under metabolic stress or drug treatments, and may reveal synthetic vulnerabilities linked to the TP53 mutant status.
Researchers can employ this model for mitochondrial calcium imaging using Rhod-2 AM, Seahorse metabolic flux analysis, JC-1 staining for mitochondrial membrane potential, and ATP luminescence assays. Co-immunoprecipitation studies with ARL2, ANT1, or MICU1 enable validation of protein interactions, while Western blotting and RT-qPCR confirm knockout and downstream effects. Additional applications include MitoTracker staining for morphology, Annexin V/PI apoptosis assays, and high-throughput drug sensitivity screening for colorectal cancer therapeutics. For further information, please contact Ascent Research.
